HIV/AIDS https://www.bioworld.com/rss en-us Approach to enhance CAR T efficacy in infectious diseases and cancer http://www.bioworld.com/articles/729932 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729932-approach-to-enhance-car-t-efficacy-in-infectious-diseases-and-cancer Transmission electron micrograph of HIV particles HIV-1 virus particles (colorized yellow) replicating from an HIV-infected H9 T cell (pink). Credit: NIAID, NIH Grant supports Tessera’s genetic approaches to HIV cure http://www.bioworld.com/articles/729794 Mon, 23 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729794-grant-supports-tesseras-genetic-approaches-to-hiv-cure DNA in drug capsules Shionogi patents new agents for HIV-1 infection http://www.bioworld.com/articles/729519 Tue, 10 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729519-shionogi-patents-new-agents-for-hiv-1-infection KLF16 as potential target for HIV management http://www.bioworld.com/articles/729376 Thu, 05 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729376-klf16-as-potential-target-for-hiv-management Transmission electron micrograph of HIV-1 virus particles HIV-1 virus particles. Credit: NIAID, CC BY 2.0 Preclinical data support continued testing of Gilead’s HIV candidate GS-3242 http://www.bioworld.com/articles/729373 Thu, 05 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729373-preclinical-data-support-continued-testing-of-gileads-hiv-candidate-gs-3242 HIV-infected cell HIV-infected cell. Credit: NIAID Anticancer drug exerts potent HIV antiviral effects http://www.bioworld.com/articles/729327 Wed, 04 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729327-anticancer-drug-exerts-potent-hiv-antiviral-effects Cross section illustration of HIV virus parts BNT-351, long-acting bNAb with potent HIV neutralization http://www.bioworld.com/articles/729134 Mon, 02 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729134-bnt-351-long-acting-bnab-with-potent-hiv-neutralization Illustration of HIV particles CROI 2026: Science and funding cuts reverse decades of progress against HIV http://www.bioworld.com/articles/729112 Fri, 27 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729112-croi-2026-science-and-funding-cuts-reverse-decades-of-progress-against-hiv HIV with graphs, numbers and map CROI 2026 highlights depression and cognitive vulnerability in HIV http://www.bioworld.com/articles/729051 Thu, 26 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729051-croi-2026-highlights-depression-and-cognitive-vulnerability-in-hiv Depression concept with human, broken brain and heavy rain MDL-001: oral polymerase inhibitor with dual HBV/HCV activity http://www.bioworld.com/articles/729032 Wed, 25 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729032-mdl-001-oral-polymerase-inhibitor-with-dual-hbv-hcv-activity CROI 2026: Neurodegeneration, the challenge of aging with HIV http://www.bioworld.com/articles/729031 Wed, 25 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729031-croi-2026-neurodegeneration-the-challenge-of-aging-with-hiv Brain and virus with chromosome DNA origami vaccine produces broadly neutralizing HIV antibodies http://www.bioworld.com/articles/728827 Fri, 13 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728827-dna-origami-vaccine-produces-broadly-neutralizing-hiv-antibodies Illustration of DNA-based vaccine for HIV The DNA-based vaccine induces antibodies to the HIV antigen (blue) without eliciting antibodies to the DNA particle (gray), whereas the protein-based vaccine generates antibodies to both the HIV antigen (blue) and the protein particle (red). Image created by Grant Knappe (MIT) based on atomic models from MIT (DNA-based vaccine) and Scripps Research (protein-based vaccine). Credits: MIT and Scripps Research Vaccines: From the toast of the town to being in the crosshairs http://www.bioworld.com/articles/727420 Tue, 23 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727420-vaccines-from-the-toast-of-the-town-to-being-in-the-crosshairs COVID-19 vial in a line of toppled dominoes HIV research is close to a cure but far from ending the pandemic http://www.bioworld.com/articles/727259 Thu, 18 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727259-hiv-research-is-close-to-a-cure-but-far-from-ending-the-pandemic Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles (blue) replicating from the plasma membrane of an H9 T cell (green). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID. Licensed under CC-BY 2.0. Peptidomimetic against drug-resistant HIV-1 http://www.bioworld.com/articles/727043 Thu, 11 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727043-peptidomimetic-against-drug-resistant-hiv-1 HIV-1 virus particle HIV-1 virus particle. Credit: National Institute of Allergy and Infectious Diseases. HIV remission after heterozygous CCR5Δ32 stem cell transplant http://www.bioworld.com/articles/726796 Tue, 02 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726796-hiv-remission-after-heterozygous-ccr532-stem-cell-transplant Illustration of HIV/AIDS virus in the bloodstream HIV remission after heterozygous CCR5Δ32 stem cell transplant Nature published three independent studies on HIV.]]> http://www.bioworld.com/articles/726666 Mon, 01 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726666-hiv-remission-after-heterozygous-ccr532-stem-cell-transplant Illustration of HIV/AIDS virus in the bloodstream Combining multiple HIV epitopes elicits broad antibody responses http://www.bioworld.com/articles/725342 Mon, 20 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/725342-combining-multiple-hiv-epitopes-elicits-broad-antibody-responses Cross section of an HIV virus particle HIV-1 targeted activator of cell kill compounds divulged in MSD patent N-oxide derivative targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of HIV infection.]]> http://www.bioworld.com/articles/724971 Wed, 08 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/724971-hiv-1-targeted-activator-of-cell-kill-compounds-divulged-in-msd-patent Deep dive nets sex differences in HIV reservoir http://www.bioworld.com/articles/724589 Wed, 24 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724589-deep-dive-nets-sex-differences-in-hiv-reservoir Transmission electron micrograph of HIV particles HIV-1 virus particles (colorized yellow) replicating from an HIV-infected H9 T cell (pink). Credit: NIAID, NIH Deep dive nets sex differences in HIV reservoir http://www.bioworld.com/articles/724431 Tue, 23 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724431-deep-dive-nets-sex-differences-in-hiv-reservoir Transmission electron micrograph of HIV particles HIV-1 virus particles (colorized yellow) replicating from an HIV-infected H9 T cell (pink). Credit: NIAID, NIH Gilead discovers new compounds for HIV infection http://www.bioworld.com/articles/724425 Mon, 22 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724425-gilead-discovers-new-compounds-for-hiv-infection NIAID grant supports pediatric vaccine for HIV http://www.bioworld.com/articles/724352 Fri, 19 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724352-niaid-grant-supports-pediatric-vaccine-for-hiv Photo of syringe with vial that reads HIV vaccine Merck’s MK-8527 enables long-acting HIV-1 prevention http://www.bioworld.com/articles/724136 Mon, 15 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724136-mercks-mk-8527-enables-long-acting-hiv-1-prevention The domino effect of cutting mRNA vaccine research http://www.bioworld.com/articles/724135 Mon, 15 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724135-the-domino-effect-of-cutting-mrna-vaccine-research Vial and syringe in row of dominoes Envelope immunogen carrying multiple epitopes for HIV http://www.bioworld.com/articles/723480 Thu, 21 Aug 2025 09:00:00 -0400 https://www.bioworld.com/articles/723480-envelope-immunogen-carrying-multiple-epitopes-for-hiv Illustration of HIV cell entry ST Pharm divulges new pyrrolopyridine compounds to treat HIV http://www.bioworld.com/articles/723377 Tue, 19 Aug 2025 09:00:00 -0400 https://www.bioworld.com/articles/723377-st-pharm-divulges-new-pyrrolopyridine-compounds-to-treat-hiv Australian researchers identify world-first treatments to prevent HTLV-1 infection http://www.bioworld.com/articles/722969 Tue, 05 Aug 2025 09:00:00 -0400 https://www.bioworld.com/articles/722969-australian-researchers-identify-world-first-treatments-to-prevent-htlv-1-infection Colorized scanning electron micrograph of a T cell HTLV-1 is a virus that infects T cells. A new study could lead to the first treatments and potential cure for HTLV-1, which affects 10 million people globally. Credit: National Institute of Allergy and Infectious Diseases. License: CC BY 2.0 Australian researchers identify world-first treatments to prevent HTLV-1 infection http://www.bioworld.com/articles/722871 Thu, 31 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/722871-australian-researchers-identify-world-first-treatments-to-prevent-htlv-1-infection Colorized scanning electron micrograph of a T cell HTLV-1 is a virus that infects T cells. A new study could lead to the first treatments and potential cure for HTLV-1, which affects 10 million people globally. Credit: National Institute of Allergy and Infectious Diseases. License: CC BY 2.0 Australian researchers identify world-first treatments to prevent HTLV-1 infection http://www.bioworld.com/articles/722687 Wed, 30 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/722687-australian-researchers-identify-world-first-treatments-to-prevent-htlv-1-infection Colorized scanning electron micrograph of a T cell HTLV-1 is a virus that infects T cells. A new study could lead to the first treatments and potential cure for HTLV-1, which affects 10 million people globally. Credit: National Institute of Allergy and Infectious Diseases. License: CC BY 2.0